Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 30;4(9):1824–1832. doi: 10.1182/bloodadvances.2020001531

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by The American Society of Hematology

PMC Copyright notice

Figure 3. — SCFA profile level modifications during aGVHD. Total SCFAs (A) and acetate (B), propionate (C), and butyrate (D) fecal levels were measured and compared between controls and aGVHD patients according to severity of GVHD (SCFAs, control vs stage 2-3, P = .0003; SCFAs, stage 1 vs stage 2-3, P = .03; acetate, control vs stage 2-3, P = .002; acetate, stage 1 vs stage 2-3, P = .036; propionate, control vs stage 2-3, P = .0009; propionate, stage 1 vs stage 2-3, P = .014; butyrate, control vs stage 1, P = .021; butyrate, control vs stage 2-3, P = .001). Statistical analyses were performed using nonparametric Wilcoxon-Mann-Whitney test with false discovery rate (FDR) correction for multiple testing. Undetectable concentrations of SCFAs were observed for 2 samples and concerned only butyrate (patients with stage 2-3 GVHD). FDR *P < .05. **P < .01, ***P < .001.